Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial
A cloud hangs over the approval of Roche's Tecentriq in the second line treatment of bladder cancer following the failure of a confirmatory Phase III trial. Meanwhile, rival product Bavencio from Merck KGaA and Pfizer has been granted accelerated approval by the FDA.
You may also be interested in...
AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.
Leadership changes at Pfizer, immuno-oncology combination updates from Merck and Roche, and the potential for Novo Nordisk to make a new offer for Ablynx – plus other highlights from upcoming biopharma earnings calls.
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.